PRPH (ProPhase Labs) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 05, 2026)


What is ProPhase Labs 5-Year Yield-on-Cost %?

ProPhase Labs PRPH -2.50% 5-Year Yield-on-Cost % is 0.00 as of Jul. 05, 2026. The stock has 5 warning signs investors should review. Among 64 Medical Diagnostics & Research companies, ProPhase Labs ranks worse than 1562498.44% on this metric.

ProPhase Labs's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for ProPhase Labs's 5-Year Yield-on-Cost % or its related term are showing as below:



PRPH's 5-Year Yield-on-Cost % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.44
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

ProPhase Labs  (OTCPK:PRPH) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

ProPhase Labs 5-Year Yield-on-Cost % Related Terms

PRPH vs IDTA, IVRO, FUNI: 5-Year Yield-on-Cost % Comparison

For the Diagnostics & Research subindustry, ProPhase Labs's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ProPhase Labs 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where ProPhase Labs's 5-Year Yield-on-Cost % falls into.


ProPhase Labs 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of ProPhase Labs is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
ProPhase Labs (PRPH) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 05, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on ProPhase Labs and its competitors. According to the industry distribution chart, ProPhase Labs ranks #999999 out of 64 companies in the Medical Diagnostics & Research industry.
Is ProPhase Labs' 5-Year Yield-on-Cost % too high?
ProPhase Labs' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, ProPhase Labs ranks #999999 out of 64 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does ProPhase Labs' 5-Year Yield-on-Cost % compare to IDTA and IVRO?
According to the Medical Diagnostics & Research industry distribution chart, ProPhase Labs ranks #999999 out of 64 companies for 5-Year Yield-on-Cost %. This places ProPhase Labs in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.44, based on 64 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on ProPhase Labs and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ProPhase Labs's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.85, compared to a current price of $0.08 — trading 90.8% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ProPhase Labs Business Description

Address 626 RXR Plaza, 6th Floor, Uniondale, NY, USA, 11556
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.